CYTX vs. AGEN, RGLS, FBIO, SABS, CRIS, BOLT, MTEM, AMGN, GILD, and VRTX
Should you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include Agenus (AGEN), Regulus Therapeutics (RGLS), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "biotechnology" industry.
Cytori Therapeutics vs.
Cytori Therapeutics (NASDAQ:CYTX) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.
Agenus received 25 more outperform votes than Cytori Therapeutics when rated by MarketBeat users. However, 73.67% of users gave Cytori Therapeutics an outperform vote while only 69.29% of users gave Agenus an outperform vote.
In the previous week, Agenus had 1 more articles in the media than Cytori Therapeutics. MarketBeat recorded 1 mentions for Agenus and 0 mentions for Cytori Therapeutics. Agenus' average media sentiment score of 0.67 beat Cytori Therapeutics' score of 0.00 indicating that Agenus is being referred to more favorably in the news media.
2.6% of Cytori Therapeutics shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 0.7% of Cytori Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Cytori Therapeutics has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
Agenus has a net margin of -145.89% compared to Cytori Therapeutics' net margin of -242.60%. Agenus' return on equity of 0.00% beat Cytori Therapeutics' return on equity.
Cytori Therapeutics has higher earnings, but lower revenue than Agenus.
Agenus has a consensus price target of $10.00, indicating a potential upside of 161.10%. Given Agenus' stronger consensus rating and higher possible upside, analysts plainly believe Agenus is more favorable than Cytori Therapeutics.
Summary
Agenus beats Cytori Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Cytori Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytori Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CYTX) was last updated on 1/21/2025 by MarketBeat.com Staff
